The Rising Role of Immunotherapy in South Asia: Current Burden and Future Prospects
Journal of Ahsania Mission of Cancer & General Hospital · 01.07.2026 · 73
DOI: 10.65292/jamcgh.2026.v2e2.05 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Ahsania Mission of Cancer & General Hospital, online erschienen am 01.07.2026. Verfasst von Prof (Brig Gen) Dr. Md. Quadrat-E- Elahi (Retd). Die Arbeit nennt 32 Literaturangaben.
Abstract (Originalsprache)
Cancer has evolved to become one of the leading non-communicable diseases in Southeast Asia, constantly being the second leading cause of death worldwide.1According to GLOBOCAN 2022 data, there were2,076,826 cancer cases and 1,346,906 deaths in 2022 across the countries—Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan, Sri Lanka. 2These figures are expected to rise significantly through the upcoming decades and projected to double by 2050. The primary treatments of cancer have long been chemotherapy and radiotherapy, but they have several drawbacks- from increased number of side effects to certain cancers being untreatable. Traditional chemotherapy is non-specific, targeting cancer cells as well as rapidly growing healthy cells, which causes toxicity in healthy tissues such as bone marrow and gastrointestinal tract. This leads to side effects like nausea, fatigue, infections, and organ dysfunction.3 Chemotherapy also carries the risk of treatment resistance, as tumors may inherently resist cytotoxic effects or develop mechanisms to evade DNA damage from radiation. Radiotherapy may not fully eradicate tumors, particularly in hypoxic or radioresistant regions, contributing to local recurrence. Both therapies involve prolonged treatment courses and potential damage to systemic or local tissue.4 Under these circumstances, the emergence of cancer immunotherapy, particularly Immune Checkpoint Inhibitors (ICIs) that targets the programmed cell death 1 (PD-1) and its ligand PD-L1 has marked a paradigm shifting advance in the field of oncology. Given the fact that cancer has a growing burden and there are limitations to treatment modalities, newer and more effective treatment options are on the rise. Immunotherapy has become a major advancement in cancer treatment, particularly after the breakthrough of Ipilimumab in 2011 to be the first Immunotherapy drug to be approved by FDA. 5 Immune checkpoint inhibitors (ICIs) are a type of Immunotherapy that targets programmed cell death 1 (PD-1) and its ligand PD-L1, whichhas marked a paradigm shift in oncology.6By boosting and restoringimmune surveillance of the body against malignant cells, Immune-Checkpoint inhibitors have achieved durable responses and significant survival benefits across multiple cancer types in important clinical trials.7 Drugs such as Pembrolizumab, Nivolumab, and Atezolizumab have gained FDA approval for a broad range of indications, including non-small cell lung cancer (NSCLC), hepatocellular carcinoma, nasopharyngeal carcinoma, cervical cancer, gastric cancer, triple-negative breast cancer (TNBC), and mismatch repair–deficient colorectal cancer—disease profiles that have the highest-burden malignancies in Southeast Asia.8 Incontrast to chemotherapy and radiotherapy, which directly work on killing the cells, immunotherapy works by helping the body’s immune system recognize and destroy cancer cells. This approach improves tumor targeting, reduces damage to healthy tissues, and can produce long-lasting treatment effects even after therapy ends.9 Treatments such as immune checkpoint inhibitors, adoptive cell transfer, monoclonal antibodies, and cancer vaccines have shown strong effectiveness against cancers including melanoma, lung cancer, and blood cancers, which has represented a paradigm-shifting advance in oncology. 10 Immunotherapy is also used with other traditional treatments such as chemotherapy in order to give a synergistic effect- Chemotherapy kills the cancer cells and Immunotherapy helps boost the immune system to recognize and prevent spread of the cancer. 11Immunotherapy is growing to become an important treatment modality by providing precision treatment. This article aims to cover the cancer burden in countries of South Asia and use of Immunotherapy in this region. 2. CANCER EPIDEMIOLOGY IN SOUTH ASIA 2.1 Cancer Burden Globocan 2022 has covered the most comprehensive epidemiology of cancer in South Asia. India has an estimated new case of 1.5 million, making it the largest cancer burden in South Asia. Pakistan with 2,00,000 new cases, has breast and oral cancers at the rise. Bangladesh, with 1,70,000 new cases, has high number of oral and lung cancers. Cervical and lung cancer is most common in Nepal, Breast and Oral cancer in Sri Lanka.12 The most common cancers in this region are breast cancer, lung cancer, cervical cancer, oral cancer, and colorectal cancer. 12While there are traditional treatments such as chemotherapy and radiotherapy, cases of relapse persist which calls for an intervention to new advancement in treatment. 13 2.2 Why Immunotherapy should be an option for cancer treatment in this region South Asia has cancer burden to those cancers that clinical evidence to the use of immunotherapy. Oral cancer accounts for 13.1% in South Asia, with 7.5% of all cancers and 177,258 new cases in 2022. Breast cancer accounted for 13.2% of all cancers in the region, with 13,000 new cases and 7000 deaths in Bangladesh. 14According to the trial, KEYNOTE 522, using immunotherapy before surgery or chemotherapy showed overall survival at 86.6% in 5 years which is a significant improvement.15According to Globocan 2022 data, lung cancer is fourth most common cancer in South Asia, accounting to approximately 130,000 new cases in the year 2022 which is likely to increase in the following years. 14The clinical trial KEYNOTE 407 showed that adding Immunotherapy significantly improved overall survival with 18.4% in the immunotherapy group in contrast to 9.7% in the chemotherapy alone group. 16 3. MODERN AGENTS IN CANCER TREATMENT 3.1 Immunotherapy In order to decrease the mortality and morbidity rate in cancer patients, newer interventions are being researched and many new treatment modalities have been discovered. In the last few decades, Immunotherapy has become a promising approach to cancer treatment. Immunotherapy primarily works by boosting the ability of the immune system to detect and destroy cancer cells by turning off mechanisms by which cancer evades the immune system. 17 There are currently different types of immunotherapy- immune checkpoint inhibitors, targeted monoclonal antibodies, cancer vaccines, oncolytic virus therapy and cytokines, all of which has a primary intention that is to boost the immune system to detect and kill cancer cells. 18 3.2 Immune Checkpoint Inhibitors Immune checkpoint inhibitors are drugs that work by blocking checkpoint proteins from binding to proteins, allowing T cells of the immune system to recognize and kill cancer cells. There are different types of immune checkpoint inhibitors that work against various checkpoint proteins such as PD-L, PD-L1, CTLA-4. Immune checkpoint inhibitors are a wonderful treatment modality as each drug has many indications which means a single drug can be used in several cancer types.19 The most commonly used immune checkpoint inhibitors are Pembrolizumab with 38 indications, Nivolumab with 17 indications, Atezolizumab with 14 indications and Durvalumab with 10 indications. 29,30,31,32 4. IMMUNE CHECKPOINT INHIBITORS- PROSPECT IN SOUTH ASIA 4.1 Pembrolizumab in South Asia Among the most widely used checkpoint inhibitors in South Asia are Pembrolizumab and Nivolumab. Pembrolizumab is commonly applied to NSCLC, melanoma, head and neck squamous cell carcinoma (HNSCC), triple-negative breast cancer, urothelial carcinoma, and MSI-H/dMMR solid tumors. A retrospective study of Pembrolizumab in advanced non-small cell cancer had significant improvements in progression-free survival, with 54% in the Pembrolizumab group and 32% in the chemotherapy alone group. 20 Asian countries with a high burden of lung cancer can benefit from such drugs. A prospective observational study at Combined Military Hospital, Dhaka, including 19 metastatic cancer patients treated with pembrolizumab, reported fewer chemotherapy-like side effects (fatigue, nausea, decreased appetite) and a 61% 6-month survival rate, indicating a tolerable safety profile and potential survival benefit. 21 Given the high burden of cancers in South Asian countries for which Pembrolizumab is indicated, the drug holds significant potential to improve treatment outcomes across the region. 4.2 Nivolumab in South Asia Nivolumab, an immune checkpoint inhibitor,hasa wide range of indications in gastric cancer, urothelial cancer, lung cancer, classical hodgkin lymphoma, renal cell carcinoma, head and neck cancer, colorectal cancer, and hepatocellular carcinoma. With a high burden of these cancers in South Asia, Nivolumab has great prospect in the region. A retrospective study conducted by theDepartment of Medical Oncology at the Tata Memorial Hospital found significant improvements in overall survival and progression-free survival for head and neck carcinoma. This indicates the use of Nivolumab in Head and neck cancers which is very common South Asia. 22 Moreover, a prospective observational study at Combined Military Hospital reported a 66% 6-month survival rate among metastatic patients with fewer adverse effects than chemotherapy. 4.3 Meta Analysis summary In context to phase 3 data, the efficacy benefits of Asian population from the checkpoint inhibitors pembrolizumab, nivolumab, atezolizumab, and durvalumab are in alignment with those of global population. The strongest molecule-specific comparative evidence is for pembrolizumab, where a systematic review/meta-regression of phase 3 trials found greater benefit in Asian vs non-Asian patients: pooled ratio of HRs 0.87; 95% CI 0.76–0.99, while PFS difference was not significant. Key efficacy signals Molecule Best Asian phase 3 evidence found Asian efficacy signal Pembrolizumab 17 OS and 11 PFS phase 3 trials in Asian vs non-Asian meta-analysis23 OS benefit may be stronger in Asian patients; PFS similar Pembrolizumab – HCC KEYNOTE-394, Asia-only phase 324 OS 14.6 vs 13.0 months, HR 0.79; PFS HR 0.74 vs placebo Nivolumab – NSCLC CheckMate 9LA Asian subgroup25 OS HR 0.33, PFS HR 0.47, ORR 57% vs 23% vs chemotherapy Atezolizumab SCLC/NSCLC IMpower133/OAK Japanese subgroup reports26 Published subgroup analyses support benefit, but accessible abstracts were less data-rich in this pass Durvalumab – SCLC CASPIANJapan subgroup27 OS numerically favored durvalumab + EP: HR 0.77, ORR 89% vs 69%; small Durvalumab/Tremelimumab – HCC HIMALAYA Asian subgroup, excluding Japan28 STRIDE OS HR 0.68 vs sorafenib; durvalumab OS HR 0.83; included India among Asian sites 5. CONCLUSION Cancer incidence in South Asia is rising rapidly, making it a major public health concern. Although chemotherapy and radiotherapy are still widely used, their limitations highlight the need for more effective and targeted approaches. Immunotherapy, particularly immune checkpoint inhibitors targeting PD-1/PD-L1, has emerged as a significant advancement in oncology, offering improved survival and durable responses in several high-burden cancers in the region.For Asian patients, there is no evidence that these agents are less effective than in global population. As for South Asian population, even though there are not many trials that directly advocates the efficacy of Immune checkpoint inhibitors in this region, there is indirect evidence so conclusions should be inferred from Asian and global data with care. Evidence from clinical trials and real-world studies supports the effectiveness of drugs such as Pembrolizumab, Nivolumab, Atezolizumab, and Durvalumab in cancers common in South Asia. However, challenges including cost, limited access, and inadequate diagnostic facilities may restrict their widespread use.Overall, immunotherapy represents a promising and transformative approach that could significantly improve cancer outcomes in South Asia with better accessibility and integration into healthcare systems.
Zitieren
APA
(Retd), P. B. G. D. M. Q. E. (2026). The Rising Role of Immunotherapy in South Asia: Current Burden and Future Prospects. Journal of Ahsania Mission of Cancer & General Hospital, 73. https://doi.org/10.65292/jamcgh.2026.v2e2.05
Vancouver
(Retd) PBGDMQE. The Rising Role of Immunotherapy in South Asia: Current Burden and Future Prospects. Journal of Ahsania Mission of Cancer & General Hospital. 2026:73. doi:10.65292/jamcgh.2026.v2e2.05
BibTeX
@article{Retd2026,
author = {(Retd), Prof (Brig Gen) Dr. Md. Quadrat-E- Elahi},
title = {The Rising Role of Immunotherapy in South Asia: Current Burden and Future Prospects},
journal = {Journal of Ahsania Mission of Cancer & General Hospital},
year = {2026},
pages = {73},
doi = {10.65292/jamcgh.2026.v2e2.05}
}
EUVIMED